SCHEMBL303054

SCHEMBL303054

[CH]1CC1c1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2103232 1.00
SCHEMBL1779485 1.00
SCHEMBL4800650 0.97 TSHR (0.42)
SCHEMBL6519587 0.97 TSHR (0.42)
SCHEMBL6468322 0.89 TSHR (0.37)
SCHEMBL6523128 0.80 TSHR (0.34)
SCHEMBL4297438 0.80 SLC18A3 (0.40)
SCHEMBL779515 0.78 SLC18A3 (0.43)
SCHEMBL1929909 0.77 SLC18A3 (0.41)
SCHEMBL17054528 0.73 MAOB (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023212650-A1 NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE THE SCRIPPS RESEARCH INSTITUTE (US) 2023-11-02 WO claimed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 US claimed
CN-114605401-A Oxygen-containing five-membered heterocyclic compound, synthesis method, pharmaceutical composition and application 江南大学 2022-06-10 CN claimed
CN-114573575-A Oxygen-containing five-membered heterocyclic compound, synthesis method, pharmaceutical composition and application 江南大学 2022-06-03 CN claimed
CN-114516867-A Oxygen-containing five-membered heterocyclic compound, synthesis method, pharmaceutical composition and application 江南大学 2022-05-20 CN claimed
WO-2022011171-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. (US) 2022-01-13 WO claimed
EP-2970119-B1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2021-11-03 EP claimed
US-20210315992-A1 ADJUVANT EFFECT OF THE TLR1/2 AGONIST DIPROVOCIM SYNERGIZES WITH CHECKPOINT-INHIBITING ANTIBODIES TO ELIMINATE DISEASE THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2021-10-14 US claimed
CN-109641878-B DIPROVOCIM: effective TLR agonist 斯克里普斯研究学院 2021-09-14 CN claimed
CN-113164445-A Adjuvant effect of the TLR1/2 agonist diprocomim synergistically potentiates checkpoint inhibitory antibodies to eliminate disease 得克萨斯系统大学评议会 2021-07-23 CN claimed
US-5849922-A Preparation of substituted alkenoic acids ELI LILLY AND COMPANY (US) 1998-12-15 US claimed
US-5763621-A Metalloproteinase inhibitors BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-06-09 US claimed
EP-0816361-A2 Preparation of substituted alkenoic acids ELI LILLY AND COMPANY (US) 1998-01-07 EP claimed
EP-0811621-A2 Carbamoyl substituted oxazoles as thromboxane receptor antagonists ELI LILLY AND COMPANY (US) 1997-12-10 EP claimed
EP-0777646-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-06-11 EP claimed
WO-1996006074-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1996-02-29 WO claimed
US-4983623-A Prolyl endopeptidase inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1991-01-08 US claimed
EP-0320753-A2 Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1989-06-21 EP claimed
EP-0035597-B1 PHARMACEUTICAL PREPARATIONS Röhm Pharma GmbH (DE) 1984-08-01 EP claimed
EP-0035597-A2 Pharmaceutical preparations Röhm Pharma GmbH (DE) 1981-09-16 EP claimed